No Data
Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $8 Price Target
Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $8 price target.
Benchmark Co. Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $8
Benchmark Co. analyst Robert Wasserman maintains $Emergent BioSolutions(EBS.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 3
What Is Going On With Emergent BioSolutions Shares?
Emergent BioSolutions (NYSE:EBS) stock is trading higher on Thursday after the company announced the sale of its facility in Baltimore-Camden to Bora Pharmaceuticals.What Happened: On Thursday prior t
Emergent to Sell Baltimore-Camden Production Site for $30M
Emergent Biosolutions Is Maintained at Buy by Benchmark
Emergent Biosolutions Is Maintained at Buy by Benchmark
Emergent BioSolutions Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/20/2024 30.93% Benchmark $5 → $8 Maintains Buy 04/11/2024 -18.17% Benchmark → $5 Reiterates Buy → Buy 0